These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25197827)

  • 1. Soluble CD163 is associated with shortened telomere length in HIV-infected patients.
    Srinivasa S; Fitch KV; Petrow E; Burdo TH; Williams KC; Lo J; Cȏté HCF; Grinspoon SK
    J Acquir Immune Defic Syndr; 2014 Dec; 67(4):414-418. PubMed ID: 25197827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.
    Burdo TH; Lo J; Abbara S; Wei J; DeLelys ME; Preffer F; Rosenberg ES; Williams KC; Grinspoon S
    J Infect Dis; 2011 Oct; 204(8):1227-36. PubMed ID: 21917896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection.
    Burdo TH; Weiffenbach A; Woods SP; Letendre S; Ellis RJ; Williams KC
    AIDS; 2013 Jun; 27(9):1387-95. PubMed ID: 23435298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy.
    Burdo TH; Lentz MR; Autissier P; Krishnan A; Halpern E; Letendre S; Rosenberg ES; Ellis RJ; Williams KC
    J Infect Dis; 2011 Jul; 204(1):154-63. PubMed ID: 21628670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.
    Beltrán LM; Muñoz Hernández R; de Pablo Bernal RS; García Morillo JS; Egido J; Noval ML; Ferrando-Martinez S; Blanco-Colio LM; Genebat M; Villar JR; Moreno-Luna R; Moreno JA
    PLoS One; 2014; 9(3):e90541. PubMed ID: 24594990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women.
    Fitch KV; Srinivasa S; Abbara S; Burdo TH; Williams KC; Eneh P; Lo J; Grinspoon SK
    J Infect Dis; 2013 Dec; 208(11):1737-46. PubMed ID: 24041790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Macrophage Activation in HIV-2-Infected Patients Is Less Affected by Antiretroviral Treatment-sCD163 in HIV-1, HIV-2, and HIV-1/2 Dually Infected Patients.
    Hønge BL; Andersen MN; Jespersen S; Medina C; Correira FG; Jakobsen MR; Laursen A; Erikstrup C; Møller HJ; Wejse C;
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):254-8. PubMed ID: 26825178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort.
    Vita S; Lichtner M; Marchetti G; Mascia C; Merlini E; Cicconi P; Vullo V; Viale P; Costantini A; DʼArminio Monforte A;
    J Acquir Immune Defic Syndr; 2017 Mar; 74(3):347-352. PubMed ID: 27828874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals.
    Knudsen TB; Ertner G; Petersen J; Møller HJ; Moestrup SK; Eugen-Olsen J; Kronborg G; Benfield T
    J Infect Dis; 2016 Oct; 214(8):1198-204. PubMed ID: 27354366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.
    Parisi SG; Andreis S; Mengoli C; Menegotto N; Cavinato S; Scaggiante R; Andreoni M; Palù G; Basso M; Cattelan AM
    Med Microbiol Immunol; 2018 Aug; 207(3-4):183-194. PubMed ID: 29523966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects.
    Zanni MV; Burdo TH; Makimura H; Williams KC; Grinspoon SK
    Clin Endocrinol (Oxf); 2012 Sep; 77(3):385-90. PubMed ID: 22098563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV.
    Fourman LT; Czerwonka N; Shaikh SD; Stanley TL; Burdo TH; Williams KC; Fitch KV; Lo J; Grinspoon SK
    AIDS; 2018 Apr; 32(7):927-932. PubMed ID: 29424780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High soluble CD163 levels correlate with disease progression and inflammation in Kenyan children with perinatal HIV-infection.
    Generoso M; Álvarez P; Kravietz A; Mwamzuka M; Marshed F; Ahmed A; Khaitan A
    AIDS; 2020 Jan; 34(1):33-38. PubMed ID: 31567161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults.
    Reid M; Ma Y; Scherzer R; Price JC; French AL; Plankey MW; Grunfeld C; Tien PC
    AIDS; 2017 Jan; 31(3):385-393. PubMed ID: 28081037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women.
    Martin GE; Gouillou M; Hearps AC; Angelovich TA; Cheng AC; Lynch F; Cheng WJ; Paukovics G; Palmer CS; Novak RM; Jaworowski A; Landay AL; Crowe SM
    PLoS One; 2013; 8(1):e55279. PubMed ID: 23365694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arterial inflammation in patients with HIV.
    Subramanian S; Tawakol A; Burdo TH; Abbara S; Wei J; Vijayakumar J; Corsini E; Abdelbaky A; Zanni MV; Hoffmann U; Williams KC; Lo J; Grinspoon SK
    JAMA; 2012 Jul; 308(4):379-86. PubMed ID: 22820791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble CD163 predicts incident chronic lung, kidney and liver disease in HIV infection.
    Kirkegaard-Klitbo DM; Mejer N; Knudsen TB; Møller HJ; Moestrup SK; Poulsen SD; Kronborg G; Benfield T
    AIDS; 2017 Apr; 31(7):981-988. PubMed ID: 28252527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased monocyte activation with age among HIV-infected long term non-progressor children: implications for early treatment initiation.
    D'Souza RR; Gopalan BP; Rajnala N; Phetsouphanh C; Shet A
    HIV Med; 2019 Sep; 20(8):513-522. PubMed ID: 31131542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hyperinsulinemia effects on systemic markers of immune activation in HIV.
    O'Malley TK; Burdo TH; Robinson JA; Fitch KV; Grinspoon SK; Srinivasa S
    AIDS; 2017 Jul; 31(12):1771-1773. PubMed ID: 28514281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Children.
    Benki-Nugent SF; Martopullo I; Laboso T; Tamasha N; Wamalwa DC; Tapia K; Langat A; Maleche-Obimbo E; Marra CM; Bangirana P; Boivin MJ; John-Stewart GC
    J Acquir Immune Defic Syndr; 2019 May; 81(1):102-109. PubMed ID: 30768490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.